Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Purpose: Sabatolimab (MBG453) and spartalizumab are monoclonal antibodies that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programed death-1 (PD-1), respectively. This phase I/II study evaluated the safety and efficacy of sabatolimab, with or without spartalizumab, in patients with advanced solid tumors. Experimental design: Primary objectives of the phase I/Ib part were to characterize the safety and estimate recommended doses for future studies (RP2Ds). Dose escalation was guided by a Bayesian (hierarchical) logistic regression model. Sabatolimab was administered intrave... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Verlag/Hrsg.: |
American Association of Cancer Research
|
Schlagwörter: | Settore MED/06 - Oncologia Medica |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26880371 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2434/839424 |